Pilot Plant Study

    RNS Number : 3939D
  Bluewater Bio International
  15 September 2008
   

    Bluewater Bio International

    Bluewater Bio and Severn Trent agree to conduct a pilot plant study of Bluewater Bio's HYBACS wastewater treatment process

    September 15, 2008

    Bluewater Bio International ("Bluewater Bio" or the "Company"), the provider of an advanced proprietary wastewater treatment solution
named HYBACS, is pleased to announce that its UK subsidiary Bluewater Bio Ltd. has signed a Letter of Intent with Severn Trent Water Ltd.
('Severn Trent') to conduct a pilot plant evaluation study of Bluewater Bio's HYBACS solution.

    Severn Trent has chosen one of its major wastewater treatment works near Birmingham for the HYBACS pilot plant which is the first
implementation of Bluewater Bio's HYBACS wastewater treatment process in Europe. The pilot plant will be a complete automatic wastewater
plant deploying the HYBACS process and will be contained within a standard shipping container. 

    The Company expects the pilot plant, which is currently under construction, to be delivered to the site within 6-8 weeks, whereupon
biological commissioning of the plant will commence. HYBACS is a nutrient removal wastewater treatment process which produces a high quality
treated effluent at a reduced capital cost and with up to a 50% reduction in power consumption relative to comparable processes. Whilst it
will take a number of months for sufficient data to be collected and analysed, should the evaluation prove successful, the Company believes
that the HYBACS process is well positioned to be highly attractive to Severn Trent or any UK water company which has the need over the
coming several years, as almost all do, to find the most reliable and cost-effective solution to nutrient removal in wastewater treatment.

    Mark Jones, Wastewater R&D Manager at Severn Trent, said "We are very pleased to be the first UK water company to collaborate with
Bluewater Bio to evaluate the potential of this new process."  

    Daniel Ishag, CEO of Bluewater Bio, commented "We are most fortunate to have the opportunity to partner with Severn Trent on our first
UK HYBACS pilot plant. Over the coming months, we hope to confirm through this and other pilot studies in Europe that HYBACS has a strong
potential to become the dominant wastewater treatment process for nutrient removal, which is one of the main themes in the European
wastewater treatment market for the foreseeable future." 

    Enquiries:

 Bluewater Bio International                    Tel: [phone]
 Daniel Ishag, CEO

 Citigate Dewe Rogerson (PR advisor)            Tel: [phone]
 Tom Baldock /Lindsay Noton 

 Strand Partners Limited (Nominated Adviser)    Tel: [phone] 
 James Harris/Angela Peace


    Notes to Editors 

    About Bluewater Bio 

    Bluewater Bio International designs and markets a highly innovative advanced biological solution to the treatment of wastewater, called
HYBACS. This system deploys a different biological approach to any internationally established wastewater treatment process. Through its
design and operation, HYBACS biologically selects a particular group of bacteria, Bacillus, with unusual natural properties which if
correctly stimulated exhibit higher biological reaction rates than other known naturally occurring bacteria. 

    The Company believes that HYBACS will be proven to be commercially superior to the majority of existing comparable treatment processes
worldwide, and is able to treat efficiently both municipal wastewater as well as a wide range of organic industrial wastewaters, including
highly concentrated livestock wastewater and the effluent from, among others, breweries, food processors, textile manufacturers, hospitals,
factories and residential developments.

    Bluewater Bio is looking to make sales of its HYBACS technology globally.

    Key benefits of the HYBACS system include: 

    HYBACS produces high quality treated wastewater, treating the biological waste in municipal wastewater down to 10 mg/L BOD (Biological
Oxygen Demand), and up to 99 per cent. treatment of the biological waste in concentrated wastewaters;

    HYBACS requires between five and 15 per cent. less capital expenditure than most widely installed comparable technologies to achieve
these performance qualities on a like-for-like basis;

    HYBACS requires between up to 30 per cent. less ongoing operating expenditure based on an overall lower energy consumption requirement
on a like-for-like basis;

    HYBACS is highly suited to plant retrofitting which makes HYBACS more suitable for various types of plant upgrading as compared to many
other advanced modern wastewater treatment processes. In applications where odour levels emanating from the plant may be an issue, the
HYBACS process removes offensive odour without the requirement for additional deodorisation facilities which involve additional capital and
operating expenditures; and

    HYBACS removes approximately twice the concentration of E. coli bacteria, compared to conventional technology which may result in
moderately reduced operating expenditure at sites where disinfection of the effluent is required.
    
    



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCDBGDCGSBGGIS